Standardized curcumin formulations in type 2 diabetes mellitus: a precision adjunct strategy targeting bioavailability, glycemic control, and immunometabolic inflammation.

Abstract

<p>Type 2 diabetes mellitus is increasingly conceptualized as an immunometabolic disorder in which hyperglycemia, insulin resistance, oxidative stress, and chronic low-grade inflammation interact synergistically to accelerate vascular and end-organ complications. Curcumin, the principal polyphenolic constituent of Curcuma longa, has attracted sustained scientific interest as an adjunct intervention given its putative effects on glycemic regulation, inflammatory signaling, and redox homeostasis. Clinical translation has been constrained by poor aqueous solubility, limited gastrointestinal absorption, rapid phase II metabolism, and inconsistent formulation quality across investigational preparations limitations extensively documented across pharmacokinetic studies and clinical reviews. This Perspective contends that curcumin must be evaluated not as a generic botanical supplement but as a standardized, formulation-dependent adjunct requiring precision in dose selection, delivery architecture, bioavailability enhancement, biomarker specification, and patient phenotyping. Emerging platforms, including curcuminoid-piperine co-formulations, phospholipid complexes, polymeric nanoparticles, and micellar systems, may substantially improve systemic exposure and therapeutic reproducibility. Evidence from randomized controlled trials and meta-analyses indicates potential improvements in fasting plasma glucose, glycated hemoglobin, insulin resistance indices, and inflammatory biomarkers, although heterogeneity in formulation composition, intervention duration, dosing strategy, and background pharmacotherapy attenuates certainty of effect. A precision adjunct framework is proposed to identify the patient subgroups, formulation classes, and inflammatory phenotypes most likely to derive clinical benefit. Future trials should prioritize standardized preparations, pharmacokinetic validation, stratified enrolment, clinically meaningful end-points, systematic safety monitoring, and rigorous integration with guideline-concordant diabetes management.</p>